ADC Therapeutics (ADCT) Total Liabilities (2019 - 2026)

ADC Therapeutics (ADCT) has reported Total Liabilities for 8 consecutive years, with $507.9 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities fell 0.57% year-over-year to $507.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $507.9 million (down 0.57% YoY) and the FY2025 annual result came in at $509.0 million, down 2.98% from the prior year.
• Total Liabilities held at $507.9 million in Q1 2026 per ADCT's latest filing, from $509.0 million in the prior quarter.
• Over the last five years, Total Liabilities for ADCT reached as high as $527.9 million in Q3 2025 and fell as low as $405.1 million in Q2 2022.
• A 5-year average of $485.9 million and a median of $507.9 million in 2026 frame the typical range for Total Liabilities.
• The largest YoY upside for Total Liabilities was 156.03% in 2022 against a maximum downside of 8.96% in 2022.
• Year by year, Total Liabilities stood at $411.4 million in 2022, then rose by 22.27% to $503.0 million in 2023, then climbed by 4.29% to $524.6 million in 2024, then dropped by 2.98% to $509.0 million in 2025, then retreated by 0.22% to $507.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $507.9 million, $509.0 million, and $527.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.